These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 37486343)

  • 21. Epithelial ovarian cancer and brain metastases: might the
    Sassu CM; Marchetti C; Russo G; Minucci A; Boccia SM; Benato A; Nero C; Piermattei A; Mattogno PP; Giannarelli D; Ferrandina G; Olivi A; Fagotti A; Scambia G
    Int J Gynecol Cancer; 2024 Jan; 34(1):88-98. PubMed ID: 38805344
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy of chemotherapy in BRCA1/2 mutation carrier ovarian cancer in the setting of PARP inhibitor resistance: a multi-institutional study.
    Ang JE; Gourley C; Powell CB; High H; Shapira-Frommer R; Castonguay V; De Greve J; Atkinson T; Yap TA; Sandhu S; Banerjee S; Chen LM; Friedlander ML; Kaufman B; Oza AM; Matulonis U; Barber LJ; Kozarewa I; Fenwick K; Assiotis I; Campbell J; Chen L; de Bono JS; Gore ME; Lord CJ; Ashworth A; Kaye SB
    Clin Cancer Res; 2013 Oct; 19(19):5485-93. PubMed ID: 23922302
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Poly (ADP-ribose) Polymerase Inhibitors Have Comparable Efficacy with Platinum Chemotherapy in Patients with BRCA-positive Metastatic Castration-resistant Prostate Cancer. A Systematic Review and Meta-analysis.
    Fazekas T; Széles ÁD; Teutsch B; Csizmarik A; Vékony B; Kói T; Ács N; Hegyi P; Hadaschik B; Nyirády P; Szarvas T
    Eur Urol Oncol; 2024 Jun; 7(3):365-375. PubMed ID: 37722977
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Rucaparib: a novel PARP inhibitor for
    Colombo I; Lheureux S; Oza AM
    Drug Des Devel Ther; 2018; 12():605-617. PubMed ID: 29606854
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A Phase II Study of Rucaparib Monotherapy in Nonmetastatic, Hormone-Sensitive Prostate Cancer Demonstrating "BRCAness" Genotype (ROAR).
    Sahu KK; Li H; Mathew Thomas V; Benson M; Boucher K; Gupta S; Kohli M; Swami U; Agarwal N; Maughan BL
    Oncologist; 2024 May; 29(5):450-e725. PubMed ID: 38452035
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Second-line olaparib maintenance therapy is associated with poor response to subsequent chemotherapy in BRCA1/2-mutated epithelial ovarian cancer: A multicentre retrospective study.
    Park J; Kim SI; Jeong SY; Kim Y; Bookman MA; Kim JW; Kim BG; Lee JY
    Gynecol Oncol; 2022 Apr; 165(1):97-104. PubMed ID: 35153073
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy of subsequent chemotherapy for patients with BRCA1/2-mutated recurrent epithelial ovarian cancer progressing on olaparib versus placebo maintenance: post-hoc analyses of the SOLO2/ENGOT Ov-21 trial.
    Frenel JS; Kim JW; Aryal N; Asher R; Berton D; Vidal L; Pautier P; Ledermann JA; Penson RT; Oza AM; Korach J; Huzarski T; Pignata S; Colombo N; Park-Simon TW; Tamura K; Sonke GS; Freimund AE; Lee CK; Pujade-Lauraine E
    Ann Oncol; 2022 Oct; 33(10):1021-1028. PubMed ID: 35772665
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Multi-Maintenance Olaparib Therapy in Relapsed, Germline BRCA1/2-Mutant High-Grade Serous Ovarian Cancer (MOLTO): A Phase II Trial.
    Morgan RD; Clamp AR; White DJ; Price M; Burghel GJ; Ryder WDJ; Mahmood RD; Murphy AD; Hasan J; Mitchell CL; Salih Z; Wheeler C; Buckley E; Truelove J; King G; Ainaoui Y; Bhaskar SS; Shaw J; Evans DGR; Kilerci B; Pearce SP; Brady G; Dive C; O'Connor JPB; Wallace AJ; Rothwell DG; Edmondson RJ; Jayson GC
    Clin Cancer Res; 2023 Jul; 29(14):2602-2611. PubMed ID: 36799931
    [TBL] [Abstract][Full Text] [Related]  

  • 29. PARP inhibitors decrease response to subsequent platinum-based chemotherapy in patients with BRCA mutated ovarian cancer.
    Rose PG; Yao M; Chambers LM; Mahdi H; DeBernardo R; Michener CM; AlHilli M; Ricci S; Vargas R
    Anticancer Drugs; 2021 Nov; 32(10):1086-1092. PubMed ID: 34520432
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bevacizumab or PARP-Inhibitors Maintenance Therapy for Platinum-Sensitive Recurrent Ovarian Cancer: A Network Meta-Analysis.
    Bartoletti M; Pelizzari G; Gerratana L; Bortot L; Lombardi D; Nicoloso M; Scalone S; Giorda G; Baldassarre G; Sorio R; Puglisi F
    Int J Mol Sci; 2020 May; 21(11):. PubMed ID: 32471250
    [TBL] [Abstract][Full Text] [Related]  

  • 31. PARP-inhibitors in BRCA-associated pancreatic cancer.
    Bhalla A; Saif MW
    JOP; 2014 Jul; 15(4):340-3. PubMed ID: 25076338
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Rapid Progression of Metastatic Pancreatic Adenocarcinoma During Platinum-Based Therapy in a Patient Harboring a Pathogenic BRCA2 Germline Variant.
    Sorscher S; Ramkissoon S
    Oncologist; 2021 Nov; 26(11):916-918. PubMed ID: 34309133
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Molecular and clinical predictors of improvement in progression-free survival with maintenance PARP inhibitor therapy in women with platinum-sensitive, recurrent ovarian cancer: A meta-analysis.
    Lee CK; Friedlander ML; Tjokrowidjaja A; Ledermann JA; Coleman RL; Mirza MR; Matulonis UA; Pujade-Lauraine E; Bloomfield R; Goble S; Wang P; Glasspool RM; Scott CL;
    Cancer; 2021 Jul; 127(14):2432-2441. PubMed ID: 33740262
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Real-world clinical data analysis of PARPi as first-line maintenance therapy in newly diagnosed epithelial ovarian cancer patients].
    Wang DF; Zhang J; Zhang C; Yu J; Shi Y; Xu SQ; Fan Y; Zhou FZ; Song SQ; Liu H; Zhang GN
    Zhonghua Fu Chan Ke Za Zhi; 2022 Sep; 57(9):641-652. PubMed ID: 36177575
    [No Abstract]   [Full Text] [Related]  

  • 35. An Effective Epigenetic-PARP Inhibitor Combination Therapy for Breast and Ovarian Cancers Independent of BRCA Mutations.
    Pulliam N; Fang F; Ozes AR; Tang J; Adewuyi A; Keer H; Lyons J; Baylin SB; Matei D; Nakshatri H; Rassool FV; Miller KD; Nephew KP
    Clin Cancer Res; 2018 Jul; 24(13):3163-3175. PubMed ID: 29615458
    [No Abstract]   [Full Text] [Related]  

  • 36. Update on PARP Inhibitors in Breast Cancer.
    Zimmer AS; Gillard M; Lipkowitz S; Lee JM
    Curr Treat Options Oncol; 2018 Apr; 19(5):21. PubMed ID: 29644491
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Chemotherapy and PARP inhibitors in heavily pretreated BRCA1/2 mutation ovarian cancer (BMOC) patients.
    Rodriguez-Freixinos V; Fariñas-Madrid L; Gil-Martin M; Barretina-Ginesta P; Romeo M; Villacampa G; Pardo B; Ahmed H; Recalde S; Piulats JM; Gómez-Plaza MC; Gil-Moreno A; Sala E; Martínez-Román S; Ponce J; Meléndez C; Carballas E; Dienstmann R; Oaknin A
    Gynecol Oncol; 2019 Feb; 152(2):270-277. PubMed ID: 30551885
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer.
    Drew Y; Ledermann J; Hall G; Rea D; Glasspool R; Highley M; Jayson G; Sludden J; Murray J; Jamieson D; Halford S; Acton G; Backholer Z; Mangano R; Boddy A; Curtin N; Plummer R
    Br J Cancer; 2016 Mar; 114(7):723-30. PubMed ID: 27002934
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A Phase I-II Study of the Oral PARP Inhibitor Rucaparib in Patients with Germline
    Kristeleit R; Shapiro GI; Burris HA; Oza AM; LoRusso P; Patel MR; Domchek SM; Balmaña J; Drew Y; Chen LM; Safra T; Montes A; Giordano H; Maloney L; Goble S; Isaacson J; Xiao J; Borrow J; Rolfe L; Shapira-Frommer R
    Clin Cancer Res; 2017 Aug; 23(15):4095-4106. PubMed ID: 28264872
    [No Abstract]   [Full Text] [Related]  

  • 40. Polyclonal BRCA2 mutations following carboplatin treatment confer resistance to the PARP inhibitor rucaparib in a patient with mCRPC: a case report.
    Simmons AD; Nguyen M; Pintus E
    BMC Cancer; 2020 Mar; 20(1):215. PubMed ID: 32171277
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.